Clinical Trials Logo

Psoriasis clinical trials

View clinical trials related to Psoriasis.

Filter by:

NCT ID: NCT05863273 Not yet recruiting - Psoriasis Clinical Trials

Real World Study on the Efficacy and Safety of Apremilast in Chinese Patients With Moderate to Severe Plaque Psoriasis, a Multi Center, Prospective, Observational Trial(REACT)

Start date: May 20, 2023
Phase:
Study type: Observational

This is a multicenter, one-arm, prospective, observational study,intended to assess evaluation of efficacy and safety of Apremilast in Chinese patients with moderate-to-severe plaque psoriasis。During this study, it is expected to collect data at at baseline and weeks 2, 6, 10, 16, and 20 after treatment。

NCT ID: NCT05858645 Not yet recruiting - Psoriasis Vulgaris Clinical Trials

Correction of Psoriatic T Cell Signatures by Deucravacitinib

Start date: July 2023
Phase: Phase 4
Study type: Interventional

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.

NCT ID: NCT05815797 Not yet recruiting - Psoriasis Vulgaris Clinical Trials

Shuiniujiao Dihuang Decoction With Variation for the Treatment of Psoriasis

Start date: May 2024
Phase: Phase 2
Study type: Interventional

Psoriasis is an inflammatory skin disease with huge negative impact on the quality of life of the patients, and has an overall prevalence of 2% to 3% in the general population. Plaques psoriasis is the most common type of the disease and presents red, well demarcated, and silvery plaques mainly localized in the umbilical and lumbosacral area as well as in the elbows, knees, and scalp. Currently, pharmacological treatments such as retinoids, corticosteroids, vitamin D analogs and biologics remain the main options for most psoriasis patients. However, side effect and high cost barred many ordinary psoriasis patients from benefiting from the treatments. A Chinese medicine formula "Shuiniujiao Dihuang Decoction with Variation (SDD)" was prescribed by Prof. Lin for many years and observed to be effective in relieving psoriasis patients' clinical manifestations. In this study, subjects with psoriasis will be randomized into treatment group of "SDD" or placebo group for 12 weeks.

NCT ID: NCT05725876 Not yet recruiting - Psoriasis Clinical Trials

Quantitative Fluorescence Molecular Imaging of Ustekinumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Crohn's Disease and Psoriasis.

VIDEO
Start date: July 1, 2023
Phase: Phase 1
Study type: Interventional

Crohn's Disease (CD) and psoriasis are chronic inflammatory diseases. Ustekinumab is a humanized monoclonal antibody. Ustekinumab is expensive and primary non-response is high in both CD and psoriasis. Currently, there are no predictors of response to ustekinumab and the actual mechanism of action has not yet been elucidated. To clarify the mechanism of action and gain a better understanding of the high primary non-response rates, the University Medical Center Groningen (UMCG) developed a tracer fluorescently labeling ustekinumab. This study aims to gain insight into ustekinumab distribution and concentrations in the gut. The current study aims to identify the ustekinumab target cells in the inflamed gut mucosa and skin using quantitative fluorescence molecular endoscopy (qFME). By gaining insight into local ustekinumab concentrations, drug distribution, and by discovering target cells, we expect to gain insight into the mechanism of action of ustekinumab.

NCT ID: NCT05716152 Not yet recruiting - Psoriasis Vulgaris Clinical Trials

Hormonal Associations in Male Patients With Psoriasis Vulgaris

Start date: February 1, 2023
Phase:
Study type: Observational

A cross sectional clinical study will be conducted on male patients with moderate and sever psoriasis vulgaris to: - Identify the pattern of serum testosterone level and tissue androgen receptors. - Evaluate the relationship between serum testosterone level, tissue androgen receptors and the severity of psoriasis vulgaris

NCT ID: NCT05695833 Not yet recruiting - Nail Psoriasis Clinical Trials

Nd:YAG Laser and Radiofrequency in Treatment of Fingernail Psoriasis

Start date: January 20, 2023
Phase: N/A
Study type: Interventional

Compare the effect of Radiofrequency to long pulsed Nd:YAG 1064 nm laser in treatment of fingernail psoriasis.

NCT ID: NCT05601492 Not yet recruiting - Psoriasis Clinical Trials

Adherence to Otezla

Start date: July 2024
Phase: Early Phase 1
Study type: Interventional

Most people with psoriasis have very limited disease, yet that disease may still have a large impact on their lives. While limited psoriasis may be amenable to topical treatment, patients are exceptionally poorly adherent to topical treatment, especially over the long run.

NCT ID: NCT05555797 Not yet recruiting - Psoriasis Clinical Trials

Excimer Laser With Topical Agents in Psoriasis Vulgaris

Start date: October 30, 2022
Phase: Phase 4
Study type: Interventional

Psoriasis is a chronic, immune-mediated disease that affects approximately 2% of the population. The development and exacerbation of psoriasis involve an interaction between multiple genetic and environmental risk factors.

NCT ID: NCT05415839 Not yet recruiting - Clinical trials for the Efficacy of Fractional Co2 Laser in Nail Psoriais

Fractional CO2 Laser Versus Pulsed Dye Laser in Nail Psoriasis

Start date: June 25, 2022
Phase: N/A
Study type: Interventional

The aim of this work is to assess the efficacy and safety of fractional CO2 laser therapy in comparison to pulsed dye laser (PDL) in the treatment of nail psoriasis.

NCT ID: NCT05381402 Not yet recruiting - Clinical trials for The Impact of COVID19 on Psoriasis Patients

Impact of COVID 19 on Psoriasis Patients

Start date: May 20, 2022
Phase:
Study type: Observational

The main objective of this work is to investigate the effect of COVID-19 pandemic on psoriasis patients. This work is designed as a cross-sectional survey based on a questionnaire directed to Egyptian psoriasis patients.